NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance

The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.